The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TCT 2021 | Transplantation in patients with myelofibrosis
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the use of stem cell transplantation in myelofibrosis as evaluated in the 2021 Transplantation & Cellular Therapy (TCT) virtual meeting. Dr Mesa explores novel therapeutic combinations in myelofibrosis, the importance of prognosticating patients that will show good responses to stem cell transplantation, and how transplantation fits into the treatment landscape of myelofibrosis. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
